carcinogenicity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
=== Preclinical === Acne vaccine – immunostimulant ADA-308 – antiandrogen (androgen receptor antagonist) Research programme: acne vulgaris therapeutics - Attillaps Pharmaceuticals – acetylcholinesterase inhibitors
=== Cherish the Light Years (2011–2012) === In April 2011, Matador Records released his second album, Cherish the Light Years. In July 2011, Cold Cave remixed "I Didn't See It Coming" by the band Belle and Sebastian. The song appeared on their 12-inch single "Come On Sister" released by Matador Records and Rough Trade Records. In April 2012, Cold Cave performed at the Solomon R. Guggenheim Museum between John Chamberlain sculptures as part of the museum's Divine Ricochet series. In October 2012, Cold Cave performed at the Getty Center.
Cloning of the YAP1 gene facilitated the identification of a modular protein domain, known as the WW domain. Two splice isoforms of the YAP1 gene product were initially identified, named YAP1-1 and YAP1-2, which differed by the presence of an extra 38 amino acids that encoded the WW domain. Apart from the WW domain, the modular structure of YAP1 contains a proline-rich region at the very amino terminus, which is followed by a TID (TEAD transcription factor interacting domain). Next, following a single WW domain, which is present in the YAP1-1 isoform, and two WW domains, which are present in the YAP1-2 isoform, there is the SH3-BM (Src Homology 3 binding motif). Following the SH3-BM is a TAD (transactivation domain) and a PDZ domain-binding motif (PDZ-BM) (Figure 1).
=== SIMBAS === In March 2011, a team of researchers from UC Berkeley, DCU and University of Valparaíso have developed lab-on-a-chip that can diagnose diseases within 10 minutes without the use of external tubing and extra components. It is called Self-powered Integrated Microfluidic Blood Analysis System (SIMBAS). It uses tiny trenches to separate blood cells from plasma (99 percent of blood cells were captured during experiments). Researchers used plastic components, to reduce manufacturing costs.
Sources: en.wikipedia.org
== Performance measures == The South African logistics sector ranks highly on a global scale, and rankings are continuing to increase. According to indices from the World Bank, as of 2026, SA's logistics infrastructure and performance are comparable to those of China and the United States. South Africa ranked joint 19th place, out of 139 countries in the 2023 World Bank Logistics Performance Index - an increase of 14 places year-over-year. There are various measures of performance for South African logistics, with a mix of indices, ranks, and other metrics from the a national and node-specific perspective. According to the Council for Scientific and Industrial Research, some of these are:
This mnemonic does not include the zero and 1 symbols, which are much easier to remember by rote (see diagram at right.) The white hair often produced by freeze branding is highly amenable to simple shapes such as angles and lines. Farrell's Alpha Angle Freeze Mark was later adopted by the Bureau of Land Management (BLM) and the U.S. Forest Service as their preferred means of tracking captured wild equids. Alpha-Angle brands can be used one at a time or set into a frame that enables all the irons needed for a particular brand to be chilled, shaken off and applied to the animal's skin at once. The Alpha-Angle system was patented by Farrell in 1972, originally for a punch gun made to tattoo the ears of livestock with Alpha-Angle symbols. The simplicity of her number system means that users can construct their irons with little difficulty, an important consideration in the American West. Alpha-Angle numerals remain the best-known and most widely used part of her branding system.
== Research directions == Research into diagnosis has aimed to develop new blood tests, including tests that could be used for those who are not currently eating gluten. These tests measure certain immune cells that react to gluten, such as CD4+ T cells and HLA-DQ-gluten tetramers. New technologies have been developed to help people follow a GFD in recent years. Food sensors, such as the Nima sensor, could help people measure the amount of gluten in food to prevent accidental gluten consumption. Testing kits that measure gluten levels in urine and waste may help measure adherence the GFD. Many strategies have been proposed to develop new treatments for coeliac disease. Altering wheat to be safer for those with coeliac disease has been explored using methods such as genetic wheat manipulation and using a chemical process (transamidation) that changes gluten proteins so they no longer trigger an immune reaction. Medications and techniques such as chitosan and AGY gluten sequestering aim to prevent gluten from interacting with the immune system. Glutenases are enzymes taken with food designed to help break down and neutralise gluten in the intestines. Glutenases being studied as of 2022 include latiglutenase–ALV003, Aspergillus niger prolyl endoprotease, Kuma030–TAK-062, and endoproptease-40. Larazotide acetate is a peptide that helps tighten the junctions between intestinal cells, reducing intestinal permeability. It helps decrease reactions to gluten by preventing gluten fragments from passing through the gut lining and triggering the immune system.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.